ActivCell sells company to Viromed Medical
Mosen/Pinneberg - North German company Viromed Medical AG is planning to acquire all shares in ActivCell Group AG, which is based in Mosen in the Swiss canton of Lucerne. The two companies have signed a term sheet to this end. The transaction is scheduled to be completed in 2024.
The ActivCell Group is to sell 100 per cent of its shares to Viromed Medical AG, which is based in the Hamburg Metropolitan Region. According to a press release, the two companies have signed a corresponding term sheet. They will “immediately” enter into further negotiations with the aim of concluding an agreement.
The transaction is scheduled to be completed in the current 2024 financial year. The purchase price is likely to be in the mid-single-digit million-euro range.
With its CellPen device series, the Swiss ActivCell Group has successfully integrated cold plasma technology into small cordless devices (“pens”), which are enabling plasma medicine to be easily applied in daily practice for the first time. According to information provided by the company, this physical treatment with direct atmospheric cold plasma in the medical field enables faster and better healing from a range of medical conditions in humans and animals.
In humans, the ActivCellPen is approved as a medical product only for the purposes of wound healing. However, the PetCellPen is used in small animal practice for dermatological problems, in orthopedics and in physiotherapy. The EquCellPen is intended for specific areas of application in horses.
ActivCell reports that the 600 participants at the 24th annual conference of the German Society for Veterinary Dermatology in Stuttgart were very interested in the topic of cold plasma therapy. The stand of ActivCell’s sales partner for Germany was very well attended as a result. On August 27, the first successful study of treating otitis externa in golden retrievers with the PetCellPen was presented at the WCVD10 World Congress in Boston.
